Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys Sells 642 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) CFO John Sakys sold 642 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $97.12, for a total value of $62,351.04. Following the completion of the transaction, the chief financial officer now directly owns 12,865 shares in the company, valued at approximately $1,249,448.80. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mesa Laboratories Stock Performance

MLAB traded up $2.83 during midday trading on Friday, hitting $95.82. 244,290 shares of the company were exchanged, compared to its average volume of 46,227. The company's 50 day simple moving average is $110.56 and its 200 day simple moving average is $124.86. The firm has a market capitalization of $523.18 million, a price-to-earnings ratio of -258.97 and a beta of 0.88. The company has a current ratio of 0.63, a quick ratio of 0.47 and a debt-to-equity ratio of 0.48. Mesa Laboratories, Inc. has a 1-year low of $83.68 and a 1-year high of $155.12.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Stockholders of record on Friday, May 30th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend was Friday, May 30th. Mesa Laboratories's dividend payout ratio (DPR) is presently -172.97%.

Institutional Investors Weigh In On Mesa Laboratories

A number of institutional investors have recently modified their holdings of MLAB. Raymond James Financial Inc. acquired a new stake in shares of Mesa Laboratories during the 4th quarter valued at about $32,677,000. Ameriprise Financial Inc. grew its position in shares of Mesa Laboratories by 191.8% during the 4th quarter. Ameriprise Financial Inc. now owns 151,862 shares of the medical instruments supplier's stock valued at $20,026,000 after acquiring an additional 99,819 shares during the period. Select Equity Group L.P. grew its position in shares of Mesa Laboratories by 439.0% during the 1st quarter. Select Equity Group L.P. now owns 73,897 shares of the medical instruments supplier's stock valued at $8,769,000 after acquiring an additional 60,186 shares during the period. Jane Street Group LLC grew its position in shares of Mesa Laboratories by 1,390.4% during the 4th quarter. Jane Street Group LLC now owns 34,399 shares of the medical instruments supplier's stock valued at $4,536,000 after acquiring an additional 32,091 shares during the period. Finally, Diamond Hill Capital Management Inc. acquired a new stake in shares of Mesa Laboratories during the 4th quarter valued at about $3,512,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 30th. Wells Fargo & Company cut their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating on the stock in a research report on Friday, May 30th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.